Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast

Annals of Allergy, Asthma and Immunology

Volumn 86, Issue 1, 2001, Pages 44-50

  Simons, F E ^b   Johnston, Lana ^a   Gu, Xiaochen ^a   Simons, Keith J ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE PHOSPHATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO;

ADULT; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INTRACUTANEOUS TEST; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SKIN ALLERGY; XEROSTOMIA;

EID: 0035138854     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62354-X     Document Type: Article

References (40)

1. Inflammatory responses in late-phase allergic reactions in the skin
2. Patterns of inflammatory responses following rechallenge in skin late-phase allergic reactions
3. Allergen-induced hyperactivity is not a feature of dermal immediate allergic reactions in contrast to reactions of airways mucosa
4. 1-blockade effect of fexofenadine
5. Fexofenadine. A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria
6. 1 receptor antagonists
7. 1 receptor blockade on the early and late response to cutaneous allergen challenge
8. Effect of cetirizine on mast cell-mediator release and cellular traffic during the cutaneous late-phase reaction
9. 1-receptor blockade on late cutaneous reactions to antigen: A double-blind, controlled study
10. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects
11. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses
12. Cellular inflammatory responses and mediator release during early developing late-phase allergic cutaneous inflammatory responses: Effects of cetirizine
13. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin
14. Accumulation of leukotriene C4 and histamine in human allergic skin reactions
15. 4 in humans
16. 4 in patients with chronic idiopathic urticaria and in normal subjects
17. 4
18. 4 in human skin
19. Leukotriene- and histamine-induced increases in vascular permeability and interstitial transport in the skin
20. 4 on cutaneous blood flow in humans
21. 4 and histamine-induced cutaneous vascular reactions in man
22. 4-induced bronchoconstriction in the human
23. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma
24. Leukotriene-receptor antagonists
25. Montelukast. A review of its therapeutic potential in persistent asthma
26. 1-receptor gene
27. 1 receptor
28. Leukotriene modifiers in chronic urticaria
29. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
30. Montelukast, a leukotriene-receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma
31. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics
32. The contribution of histamine and leukotrienes to exercise induced airway obstruction in asthmatics
33. Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis
34. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines
35. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen
36. Montelukast reduces airway eosinophilic inflammation in asthma: A randomized, controlled trial
37. Bronchial biopsy specimen variability: Requirement for large sample size and repeated measurements to improve reliability
38. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
39. Exhaled nitric oxide before and after montelukast sodium therapy in school age children with chronic asthma: A preliminary study
40. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma